Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q07955: Variant p.Val160Met

Serine/arginine-rich splicing factor 1
Gene: SRSF1
Feedback?
Variant information Variant position: help 160 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Valine (V) to Methionine (M) at position 160 (V160M, p.Val160Met). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In NEDFBA; likely pathogenic. Any additional useful information about the variant.


Sequence information Variant position: help 160 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 248 The length of the canonical sequence.
Location on the sequence: help HMREAGDVCYADVYRDGTGV V EFVRKEDMTYAVRKLDNTKF The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         HMREAGDVCYADVYRDGTGVVEFVRKEDMTYAVRKLDNTKF

Mouse                         HMREAGDVCYADVYRDGTGVVEFVRKEDMTYAVRKLDNTKF

Pig                           HMREAGDVCYADVYRDGTGVVEFVRKEDMTYAVRKLDNTKF

Bovine                        HMREAGDVCYADVYRDGTGVVEFVRKEDMTYAVRKLDNTKF

Chicken                       HMREAGDVCYADVFRDGTGVVEFVRKEDMTYAVRKLDNTKF

Xenopus tropicalis            HMREAGDVCYADVFRDGTGVVEFVRKEDMTYAVRKLDNTKF
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 248 Serine/arginine-rich splicing factor 1
Domain 121 – 195 RRM 2
Modified residue 179 – 179 N6-acetyllysine
Mutagenesis 162 – 162 F -> A. In AV; loss of ability to activate splicing. Great reduction in splice site switching activity and no effect on RNA-binding.
Mutagenesis 162 – 162 F -> D. Reduced nucleocytoplasmic shuttling; when associated with D-190.
Mutagenesis 180 – 180 F -> D. Reduced nucleocytoplasmic shuttling; when associated with D-162.
Beta strand 158 – 164



Literature citations
SRSF1 haploinsufficiency is responsible for a syndromic developmental disorder associated with intellectual disability.
Bogaert E.; Garde A.; Gautier T.; Rooney K.; Duffourd Y.; LeBlanc P.; van Reempts E.; Tran Mau-Them F.; Wentzensen I.M.; Au K.S.; Richardson K.; Northrup H.; Gatinois V.; Genevieve D.; Louie R.J.; Lyons M.J.; Laulund L.W.; Brasch-Andersen C.; Maxel Juul T.; El It F.; Marle N.; Callier P.; Relator R.; Haghshenas S.; McConkey H.; Kerkhof J.; Cesario C.; Novelli A.; Brunetti-Pierri N.; Pinelli M.; Pennamen P.; Naudion S.; Legendre M.; Courdier C.; Trimouille A.; Fenzy M.D.; Pais L.; Yeung A.; Nugent K.; Roeder E.R.; Mitani T.; Posey J.E.; Calame D.; Yonath H.; Rosenfeld J.A.; Musante L.; Faletra F.; Montanari F.; Sartor G.; Vancini A.; Seri M.; Besmond C.; Poirier K.; Hubert L.; Hemelsoet D.; Munnich A.; Lupski J.R.; Philippe C.; Thauvin-Robinet C.; Faivre L.; Sadikovic B.; Govin J.; Dermaut B.; Vitobello A.;
Am. J. Hum. Genet. 110:790-808(2023)
Cited for: VARIANTS NEDFBA LEU-24; 28-ARG--THR-248 DEL; 33-GLU--THR-248 DEL; VAL-40; ASN-44; THR-70; 77-TYR--THR-248 DEL; ARG-84; MET-160 AND ARG-183; INVOLVEMENT IN NEDFBA;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.